Two new studies offer more validation that prime editing and base editing have the potential to permanently fix a gene variant associated with the rare disease phenylketonuria. In two separate papers ...
One of the winners of the 2026 ASGCT Catalyst Award, Kiran Musunuru, MD, PhD, delivered a sobering lecture on the legacy of ...
With several potential therapies, including Sepiapterin (PTC Therapeutics (PTCT)), NGGT002 (NGGT), JNT-517 (Jnana Therapeutics), Pegvaliase (BioMarin), and others under investigation, the ...
Phenylketonuria (PKU) is an autosomal recessive disorder that results in decreased metabolism of the amino acid phenylalanine. Untreated PKU can lead to intellectual disability, seizures, behavioral ...
End-to-end pipelines and regulatory advances aim to expand gene editing to broad patient populations Ajay Gannerkote, ...
Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.
Aurora Therapeutics today announced its official launch to transform personalized gene editing from a one-patient breakthrough into a scalable model capable of bringing therapies to millions of ...
CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported financial ...
The total phenylketonuria treatment market size is expected to grow positively by 2034 in the leading markets. The United States accounts for the largest market size of phenylketonuria, in comparison ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results